{{Short description|Combination drug for HIV}} {{About|the combination medication elvitegravir/cobicistat/emtricitabine/tenofovir ''disoproxil''|the combination medication elvitegravir/cobicistat/emtricitabine/tenofovir ''alafenamide''|Tenofovir alafenamide#combinations}} {{Use dmy dates|date=July 2024}} {{cs1 config |name-list-style=vanc |display-authors=6}} {{Drugbox | type = combo
| component1 = Elvitegravir | class1 = Integrase inhibitor | component2 = Cobicistat | class2 = Cytochrome P450 inhibitor | component3 = Emtricitabine | class3 = Reverse-transcriptase inhibitor | component4 = Tenofovir disoproxil | class4 = Reverse-transcriptase inhibitor
<!--Clinical data --> | tradename = Stribild | Drugs.com = {{Drugs.com|ppa|elvitegravir-cobicistat-emtricitabine-and-tenofovir-disoproxil-fumarate}} | MedlinePlus = | pregnancy_AU = B3 | routes_of_administration = By mouth
| legal_AU = S4 | legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> | legal_UK = POM | legal_US = Rx-only | legal_US_comment = <ref name="Stribild FDA label">{{cite web | title=Stribild- elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate tablet, film coated | website=DailyMed | date=16 September 2021 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=74ae2a93-b267-444c-8f0f-a2a6522260ee | access-date=24 July 2024}}</ref> | legal_EU = Rx-only | legal_EU_comment = <ref name="Stribild EPAR">{{cite web | title=Stribild EPAR | website=European Medicines Agency | date=13 June 2013 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/stribild | access-date=24 July 2024}}</ref> | legal_status =
<!--Identifiers --> | CAS_number = 1430117-57-9 | ATCvet = | ATC_prefix = J05 | ATC_suffix = AR09 | PubChem = | DrugBank = | ChemSpiderID = none | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D10756 }}
'''Elvitegravir/cobicistat/emtricitabine/tenofovir''', sold under the brand name '''Stribild''', also known as the '''Quad''' '''pill''', is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. Elvitegravir, emtricitabine and tenofovir disoproxil directly suppress viral reproduction. Cobicistat increases the effectiveness of the combination by inhibiting the liver and gut wall enzymes that metabolize elvitegravir. It is taken by mouth. It is manufactured by Gilead Sciences.
Serum creatinine (a marker of kidney function) may increase with use of elvitegravir/cobicistat/emtricitabine/tenofovir. This is caused by cobicistat's inhibition of tubular secretion in the nephron.
== Society and culture == === Legal status === Elvitegravir/cobicistat/emtricitabine/tenofovir gained approval by the U.S. Food and Drug Administration (FDA) in August 2012, for use in adults starting antiretroviral treatment for the first time as part of the fixed dose combination.{{cn|date=September 2022}}
=== Economics === Gilead's stated wholesale price of Stribild is {{US$|28,500}} per patient, per year. Gilead maintains that its pricing is comparable to other HIV medications on the market. Elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild) is priced at 39 percent higher than emtricitabine/rilpivirine/tenofovir (Complera), a three-drug HIV regimen approved a year earlier. At the time of Complera's approval, there were concerns about the {{US$|20,500}} wholesale cost of efavirenz/emtricitabine/tenofovir (Atripla), which is marketed by Gilead and Bristol-Myers Squibb. HIV drug prices have increased substantially. Atripla, a combination therapy released in 2006, was priced at {{US$|13,800}} per person, per year. Atripla's wholesale prices have risen to the level of Complera's at {{US$|20,500}}.
==References== {{reflist}}
{{Antiretroviral drug}} {{Portal bar | Medicine | Viruses }} {{Authority control}}
{{DEFAULTSORT:Elvitegravir Cobicistat Emtricitabine Tenofovir Disoproxil}} Category:CYP3A4 inhibitors Category:Fixed dose combination (antiretroviral) Category:Gilead Sciences Category:Hepatotoxins